Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study
The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.
Are you Eligible? (Inclusion Criteria)
- Patient has signed and dated the informed consent.
- Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
- Patient agrees to return for the required follow-up assessments.
Claudia Musat MD
Columbia University Medical Center
161 Fort Washington Avenue
Herbert Irving Pavilion 5-548
New York, NY 10032